India’s GLP-1 market tops ₹220 crore as tirzepatide surges and semaglutide generics multiply
India’s GLP-1 drug market reached more than ₹220 crore in sales in the year to July, up 235%. Tirzepatide sales rose over tenfold, while 33 generic injectable brands intensified competition in semaglutide alongside Ozempic and Wegovy.
The brand move
India’s GLP-1 drug market crossed ₹220 crore in sales in the year to July, growing 235%. Tirzepatide sales rose more than tenfold, while 33 generic injectable brands intensified semaglutide competition alongside Ozempic and Wegovy.
The numbers
- ₹220 crore market sales in the year to July
- 235% market growth
- Tirzepatide sales increased more than tenfold over the past year
- 33 generic injectable brands compete in semaglutide
Why it matters for the brand
India’s fast-growing GLP-1 market is becoming a crowded retail-pharmacy category, requiring strong availability, patient education and differentiation as generic semaglutide brands proliferate.
What to track next
- Further launches of semaglutide generics and changes in their monthly therapy pricing.
- Tirzepatide supply availability, new strengths and expansion beyond major urban markets.
- Indian regulatory actions on GLP-1 marketing, obesity indications, online dispensing, counterfeit products and cold-chain standards.
- Prescription refill and discontinuation rates after the first three to six months of treatment.
- Expansion of insurer, employer-health or hospital-program reimbursement for obesity management.
The counter-case
The headline growth may overstate durable demand: ₹220 crore remains a small, urban, cash-pay market, and tenfold tirzepatide growth likely reflects a low launch base, inventory stocking and broader availability rather than sustained patient adoption. Semaglutide brand proliferation can also trigger rapid price erosion, fragmented prescriptions, discounting and weaker profitability rather than expanding the category’s value. High monthly treatment costs, supply constraints, discontinuation rates and safety monitoring needs could limit repeat use.